 |
|
Underpowered Clinical Trials of Antiretroviral Treatment
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Yeni and colleagues make the following 2 statements about underpowered trials in describing updated recommendations of the International AIDS Society-USA Panel for the treatment of adult HIV infection1: (1) "Nevirapine has been studied in the ATLANTIC trial . . . . Although not powered to provide definitive conclusions, the results suggested that activity of nevirapine in a multidrug regimen was similar to that of indinavir." (2) "Comparability in viral suppression at 36 weeks between nevirapine-containing and nelfinavir-containing regimens (each with 2 nRTIs [nucleoside reverse transcriptase inhibitors) has been reported." In our opinion, both statements are misleading. In addition to other concerns about underpowered trials,2 such results may also be used to support questionable therapeutic practices.
We have calculated confidence intervals (CIs) for the difference in the aforementioned trials. In the ATLANTIC study,3 the CIs for the difference in the percentage of patients with less than . . . [Full Text of this Article]
RELATED ARTICLES
The Continuing Unethical Conduct of Underpowered Clinical Trials
Scott D. Halpern, Jason H. T. Karlawish, and Jesse A. Berlin
JAMA. 2002;288(3):358-362.
ABSTRACT
| FULL TEXT
Antiretroviral Treatment for Adult HIV Infection in 2002: Updated Recommendations of the International AIDS Society-USA Panel
Patrick G. Yeni, Scott M. Hammer, Charles C. J. Carpenter, David A. Cooper, Margaret A. Fischl, Jose M. Gatell, Brian G. Gazzard, Martin S. Hirsch, Donna M. Jacobsen, David A. Katzenstein, Julio S. G. Montaner, Douglas D. Richman, Michael S. Saag, Mauro Schechter, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, and Paul A. Volberding
JAMA. 2002;288(2):222-235.
ABSTRACT
| FULL TEXT
|
